Grey Fox Wealth Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Grey Fox Wealth Advisors’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-2,485	Closed	-$207K	–	103
2023 Q2	$207K	Sell	2,485 -171	-6%	-$14.3K	0.11%	98
2023 Q1	$202K	Hold	2,656	–	–	0.12%	95
2022 Q4	$220K	Buy	+2,656	New	+$215K	0.15%	83

Other funds holding XBI

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Grey Fox Wealth Advisors's XBI Position: Q3 2023 in Review

Grey Fox Wealth Advisors sold out of State Street SPDR S&P Biotech ETF (XBI) in Q3 2023, closing a stake of 2,485 shares — an estimated $207K sold.

Grey Fox Wealth Advisors first reported a position in XBI in Q4 2022 and held it in 3 quarters. The position peaked at $220K in Q4 2022. 677 funds tracked by Wall St. Rank hold XBI as of Q3 2023.

Grey Fox Wealth Advisors reported no remaining State Street SPDR S&P Biotech ETF position as of Q3 2023 after selling out during the quarter.
Grey Fox Wealth Advisors sold 2,485 State Street SPDR S&P Biotech ETF shares in Q3 2023, an estimated $207K.
Grey Fox Wealth Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q4 2022 and held it in 3 quarters.
Grey Fox Wealth Advisors's State Street SPDR S&P Biotech ETF position peaked at $220K in Q4 2022.
677 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2023.

Based on Grey Fox Wealth Advisors's 13F filing for Q3 2023, filed 24 Oct 2023.